These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 8711985

  • 1. Sodium valproate in severe migraine and tension-type headache: an open study of long-term efficacy and correlation with blood levels.
    Lenaerts M, Bastings E, Sianard J, Schoenen J.
    Acta Neurol Belg; 1996 Jun; 96(2):126-9. PubMed ID: 8711985
    [Abstract] [Full Text] [Related]

  • 2. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience.
    Stillman MJ, Zajac D, Rybicki LA.
    Headache; 2004 Jan; 44(1):65-9. PubMed ID: 14979885
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine.
    Waberzinek G, Marková J, Mastík J.
    Neuro Endocrinol Lett; 2007 Feb; 28(1):59-64. PubMed ID: 17277725
    [Abstract] [Full Text] [Related]

  • 4. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.
    Tanen DA, Miller S, French T, Riffenburgh RH.
    Ann Emerg Med; 2003 Jun; 41(6):847-53. PubMed ID: 12764341
    [Abstract] [Full Text] [Related]

  • 5. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 6. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

  • 7. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group.
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [Abstract] [Full Text] [Related]

  • 8. Valproate versus flunarizine in migraine prophylaxis: a randomized, double-open, clinical trial.
    Mitsikostas DD, Polychronidis I.
    Funct Neurol; 1997 Apr; 12(5):267-76. PubMed ID: 9439944
    [Abstract] [Full Text] [Related]

  • 9. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.
    Headache; 1998 Mar; 38(3):173-83. PubMed ID: 9563207
    [Abstract] [Full Text] [Related]

  • 10. The prophylactic effect of valproate on glyceryltrinitrate induced migraine.
    Tvedskov JF, Thomsen LL, Iversen HK, Gibson A, Wiliams P, Olesen J.
    Cephalalgia; 2004 Jul; 24(7):576-85. PubMed ID: 15196300
    [Abstract] [Full Text] [Related]

  • 11. [Preventive treatment of migraine and chronic tension headache with moclobemide].
    Meienberg O, Amsler F.
    Praxis (Bern 1994); 1997 Jul 02; 86(27-28):1107-12. PubMed ID: 9324719
    [Abstract] [Full Text] [Related]

  • 12. Prevalence of migraine and response to sumatriptan in patients self-reporting tension/stress headache.
    Kaniecki R, Ruoff G, Smith T, Barrett PS, Ames MH, Byrd S, Kori S.
    Curr Med Res Opin; 2006 Aug 02; 22(8):1535-44. PubMed ID: 16870078
    [Abstract] [Full Text] [Related]

  • 13. Short-term outcomes of tension type and migraine headache in children.
    Sri-udomkajorn S, Ruangsuwan S.
    J Med Assoc Thai; 2008 Oct 02; 91 Suppl 3():S104-8. PubMed ID: 19253504
    [Abstract] [Full Text] [Related]

  • 14. Effects of valproate on vestibular symptoms and electronystagmographic findings in migraine patients.
    Celiker A, Bir LS, Ardiç N.
    Clin Neuropharmacol; 2007 Oct 02; 30(4):213-7. PubMed ID: 17762318
    [Abstract] [Full Text] [Related]

  • 15. Medication overuse headache and chronic migraine in a specialized headache centre: field-testing proposed new appendix criteria.
    Zeeberg P, Olesen J, Jensen R.
    Cephalalgia; 2009 Feb 02; 29(2):214-20. PubMed ID: 18823364
    [Abstract] [Full Text] [Related]

  • 16. The prognosis of childhood headache: a 20-year follow-up.
    Brna P, Dooley J, Gordon K, Dewan T.
    Arch Pediatr Adolesc Med; 2005 Dec 02; 159(12):1157-60. PubMed ID: 16330740
    [Abstract] [Full Text] [Related]

  • 17. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache.
    Mathew NT, Kailasam J, Meadors L.
    Headache; 2008 Feb 02; 48(2):194-200. PubMed ID: 17868356
    [Abstract] [Full Text] [Related]

  • 18. Sodium Valproate versus Propranolol in paediatric migraine prophylaxis.
    Ashrafi MR, Shabanian R, Zamani GR, Mahfelati F.
    Eur J Paediatr Neurol; 2005 Feb 02; 9(5):333-8. PubMed ID: 16120482
    [Abstract] [Full Text] [Related]

  • 19. Dextroamphetamine pilot crossover trials and n of 1 trials in patients with chronic tension-type and migraine headache.
    Haas DC, Sheehe PR.
    Headache; 2004 Feb 02; 44(10):1029-37. PubMed ID: 15546268
    [Abstract] [Full Text] [Related]

  • 20. Duration of migraine is a predictor for response to botulinum toxin type A.
    Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW.
    Headache; 2005 Apr 02; 45(4):308-14. PubMed ID: 15836566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.